DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for invasive breast ductal carcinoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInvasive breast ductal carcinoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for invasive breast ductal carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BRCA2 DNA repair associated (BRCA2) — BRCA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8PBC · 2.61 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
The 2003 chapter states that over 90 per cent of breast carcinoma arises from the epithelium of the terminal duct and lobule, and that in the United Kingdom breast cancer causes over 15,000 deaths annually. No specific survival or response rates are given. The same year’s review of pre-invasive disease reports that atypical ductal hyperplasia and ductal carcinoma in situ are precursor lesions that are molecularly similar to adjacent invasive breast cancer, based on array-based comparative genomic hybridization, RNA expression profiling, and proteomic analyses. That review does not provide sample sizes or quantitative outcomes.
The 2022 overview of de-escalation in breast cancer management discusses the possibility of less radical treatment, or even no treatment, for ductal carcinoma in situ and invasive breast cancer, provided that oncologic outcomes are equivalent to standard therapies. It notes that identifying which patients benefit from de-escalation requires particular care, but it does not report any trial results, response rates, or survival data. No drug is mentioned in any of the three abstracts.
What is still missing is any randomised trial evidence comparing de-escalated strategies to standard therapy for invasive breast ductal carcinoma, any validated molecular or imaging method to stratify patients who can safely avoid or reduce treatment, and the funding to conduct such trials with adequate follow-up.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Breast Cancer Research · 2003 · 26 citations · open access
The diagnosis and management of pre-invasive breast disease: Promise of new technologies in understanding pre-invasive breast lesions
AbstractArray-based comparative genomic hybridization, RNA expression profiling, and proteomic analyses are new molecular technologies used to study breast cancer. Invasive breast cancers were originally evaluated because they provided ample quantities of DNA, RNA, and protein. The application of these technologies to pre-invasive breast lesions is discussed, including methods that facilitate their implementation. Data indicate that atypical ductal hyperplasia and ductal carcinoma in situ are precursor lesions molecularly similar to adjacent invasive breast cancer. It is expected that molecular technologies will identify breast tissue at risk for the development of unfavorable subtypes of invasive breast cancer and reveal strategies for targeted chemoprevention or eradication.
De-Escalating the Management of In Situ and Invasive Breast Cancer
AbstractIt is necessary to identify appropriate areas of de-escalation in breast cancer treatment to minimize morbidity and maximize patients' quality of life. Less radical treatment modalities, or even no treatment, have been reconsidered if they offer the same oncologic outcomes as standard therapies. Identifying which patients benefit from de-escalation requires particular care, as standard therapies will continue to offer adequate cancer outcomes. We provide an overview of the literature on the de-escalation of treatment of ductal carcinoma in situ (DCIS), local treatment of breast cancer, and surgery after neoadjuvant systemic therapy. De-escalation of breast cancer treatment is a key area of investigation that will continue to remain a priority. Improvements in understanding the natural history and biology of breast cancer, imaging modalities, and adjuvant treatments will expand this even further. Future efforts will continue to challenge us to consider the true role of various treatment modalities.
Oxford University Press eBooks · 2003 · 0 citations
Breast cancer
AbstractThis chapter discusses one of the most fatal diseases common to women, breast cancer. In the United Kingdom, breast cancer is responsible for the deaths of over 15,000 annually. Over 90 per cent of the breast carcinoma arises from the epithelium of the terminal duct and lobule. In this chapter, the emphasis is on the identifiable causes of invasive carcinoma of the breast. The chapter also provides an outline review of the treatment approaches employed in the early and late periods of the disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
